CN101708237B - Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof - Google Patents

Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof Download PDF

Info

Publication number
CN101708237B
CN101708237B CN2009103123939A CN200910312393A CN101708237B CN 101708237 B CN101708237 B CN 101708237B CN 2009103123939 A CN2009103123939 A CN 2009103123939A CN 200910312393 A CN200910312393 A CN 200910312393A CN 101708237 B CN101708237 B CN 101708237B
Authority
CN
China
Prior art keywords
radix
parts
rhizoma
supplementing
crude drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009103123939A
Other languages
Chinese (zh)
Other versions
CN101708237A (en
Inventor
潘畅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2009103123939A priority Critical patent/CN101708237B/en
Publication of CN101708237A publication Critical patent/CN101708237A/en
Application granted granted Critical
Publication of CN101708237B publication Critical patent/CN101708237B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the field of medicament, and particularly relates to a medicinal composition used for tonifying qi and invigorating pulse, a preparation method thereof and application thereof. The invention provides a brand-new medicinal composition with functions of tonifying qi and invigorating pulse for treating cardiovascular and cerebrovascular diseases. The medicinal composition is prepared from the following raw material medicaments in part by weight: 9 to 16 parts of astragalus, 2 to 5 parts of acanthopanax bark, 1 to 5 parts of rhubarb, 2 to 5 parts of hawthorn fruit, 3 to 6 parts of Sanchi, 2 to 5 parts of Szechuan lovage rhizome, and 2 to 9 parts of Chinese angelica. The medicinal composition has the effects of tonifying original qi, tonifying spleen and dredging channels, and can be used for treating the diseases such as coronary disease (myocardial infarction and angina pectoris), ischemic and hemorrhagic cerebrovascular accidents (cerebral infarction and cerebral hemorrhage), high blood pressure, hyperlipidaemia, fatty liver and the like.

Description

Be used for pharmaceutical composition of supplementing qi and invigorating vasculum and its production and use
Technical field
The invention belongs to field of medicaments, be specifically related to pharmaceutical composition that is used for supplementing qi and invigorating vasculum and its production and use.
Background technology
So-called cardiovascular and cerebrovascular disease is exactly cardiovascular and cerebrovascular disease general designation.
Cardiovascular and cerebrovascular disease is a kind of serious threat mankind, and particularly the commonly encountered diseases of middle-aged and elderly people health more than 50 years old even use most advanced, perfect at present treatment means, still can have the cerebrovascular accident survivor life more than 50% not take care of oneself fully.Every year is died from the number of cardiovascular and cerebrovascular disease up to 1,500 ten thousand people in the whole world, occupies various causes of the death first place.Cardiovascular and cerebrovascular disease has " sickness rate height, disability rate height, mortality rate height.The relapse rate height, complication is many ", promptly the characteristics of " four is high by more than " are present, and China cardiovascular and cerebrovascular disease patient has surpassed 2.7 hundred million people.
At present, the report that the method treatment cardiovascular and cerebrovascular disease of a lot of employing tcm treatment according to syndrome differentiation is arranged, as main component is the BUCHANG NAOXINTONG of the Radix Astragali, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Semen Persicae, Flos Carthami, Olibanum (system), Myrrha (processed), Caulis Spatholobi, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Ramulus Mori, Pheretima, Scorpio, Hirudo, has the effect of benefiting QI for activating blood circulation, disperse blood stasis and dredge collateral; Be used for blood stagnancy due to deficiency of QI, apoplexy apoplex involving the channels and collaterals, hemiplegia, numb limbs and tense tendons, facial hemiparalysis due to the venation block, the stiff tongue language is stuttering and obstruction of qi in the chest and cardialgia, uncomfortable in chest, cardiopalmus, breathe hard etc., and cerebral infarction, angina pectoris belong to above-mentioned patient; NAOXINTONG JIAONANG is cut, low cut viscosity, plasma viscosity, reduced viscosity, platelet adhesion rate remarkable reduction effect is all arranged the whole blood height of " blood stasis " model; Can suppress the inductive platelet aggregation of ADP; Can obviously suppress thrombosis, and an actual dose-effect relationship is arranged; Obviously the cerebral blood flow increasing amount obviously reduces cerebral vascular resistance, obviously prolongs clotting time.A kind of Chinese medicine composition that is used for cardiovascular and cerebrovascular disease of Chinese patent application (CN1977908A) discloses part by Radix Astragali 40-160, Pheretima 5-20 part, Radix Angelicae Sinensis 5-20 part, Rhizoma Chuanxiong 5-20 part, Semen Persicae 5-20 part, Flos Carthami 5-20 part, Radix Salviae Miltiorrhizae 15-60 part, the medicine that Radix Cyathulae 5-20 part is formed; Be used for clinically coronary heart disease, angina pectoris, uncomfortable in chest, breathe hard, gloomyly have a pain, and heart and brain blood such as all kinds of heart infarction, cerebral infarction sequela. the pipe disease.
Summary of the invention
Technical problem solved by the invention provides a kind of pharmaceutical composition of effect brand-new, that have supplementing qi and invigorating vasculum, is used for the treatment of cardiovascular and cerebrovascular disease.
Pharmaceutical composition of the present invention is to be prepared from by following materials of weight proportions medicine: Radix Astragali 9-16 part, Cortex Acanthopancis 2-5 part, Radix Et Rhizoma Rhei 1-5 part, Fructus Crataegi 2-5 part, Radix Notoginseng 3-6 part, Rhizoma Chuanxiong 2-5 part, Radix Angelicae Sinensis 2-9 part.
Pharmaceutical composition of the present invention has tonifying vital QI, effect turbid, dredging the meridian is washed in spleen invigorating, can be used for treating coronary heart disease (myocardial infarction, angina pectoris), ischemic and hemorrhagic cerebrovaseular accident (cerebral infarction, cerebral hemorrhage), hypertension, hyperlipemia, diseases such as fatty liver.
The present invention also provides this preparation of drug combination method, specifically is to add water, decocts crude drug according to a conventional method, gets decoction liquor, filters, and adds acceptable accessories and makes medicament;
Perhaps, pulverize crude drug, mix, add acceptable accessories and make powder, tablet, capsule, pill.
This method adopts reasonable method extraction main active wherein according to the characteristic of crude drug, makes therapeutic effect more stable, controlled.
The specific embodiment
Below by specific description of embodiments of the present invention the explanation but do not limit the present invention.
Pharmaceutical composition of the present invention is to be prepared from by following materials of weight proportions medicine: Radix Astragali 9-16 part, Cortex Acanthopancis 2-5 part, Radix Et Rhizoma Rhei 1-5 part, Fructus Crataegi 2-5 part, Radix Notoginseng 3-6 part, Rhizoma Chuanxiong 2-5 part, Radix Angelicae Sinensis 2-9 part.Active component floats in this amount ranges all can realize treating the purpose of cardiovascular and cerebrovascular disease.
Find that through inventor's long-term practice 12 parts of the Radixs Astragali, 3 parts of Cortex Acanthopanciss, 2 parts of Radix Et Rhizoma Rhei, 3 parts of Fructus Crataegis, 4 parts of Radix Notoginseng, 3 parts of Rhizoma Chuanxiongs, 3 parts of effects of Radix Angelicae Sinensis are clearer and more definite, more stable.
Further preferred, in order to strengthen, stablize curative effect, crude drug also contains Radix Ginseng, Radix Bupleuri, Rhizoma Alismatis, Flos Lonicerae, Fructus Trichosanthis, Radix Puerariae, Radix Salviae Miltiorrhizae, and the crude drug weight proportion is as follows:
Radix Astragali 9-16 part, Radix Ginseng 3-5 part, Cortex Acanthopancis 2-5 part, Radix Bupleuri 1-5 part, Rhizoma Alismatis 1-5 part, Flos Lonicerae 1-3 part, Fructus Trichosanthis 1-3 part, Radix Et Rhizoma Rhei 1-5 part, Radix Puerariae 1-3 part, Fructus Crataegi 2-5 part, Radix Notoginseng 3-6 part, Radix Salviae Miltiorrhizae 3-9 part, Rhizoma Chuanxiong 2-5 part, Radix Angelicae Sinensis 2-9 part.
Further preferred, the above-mentioned raw materials medicine adopts the weight proportion of 12 parts of the following Radixs Astragali, 5 parts of Radix Ginsengs, 3 parts of Cortex Acanthopanciss, 2 parts of Radix Bupleuri, 2 parts of Rhizoma Alismatis, 2 parts of Flos Loniceraes, 2 parts of Fructus Trichosanthis, 2 parts of Radix Et Rhizoma Rhei, 1 part of Radix Puerariae, 3 parts of Fructus Crataegis, 4 parts of Radix Notoginseng, 4 parts of Radix Salviae Miltiorrhizaes, 3 parts of Rhizoma Chuanxiongs, 3 parts of Radix Angelicae Sinensis clearer and more definite, more stable.
For the ease of taking, can on the basis of crude drug, add acceptable accessories and make common dosage forms, as granule, tablet, capsule, pill or oral liquid etc.
Preparation of drug combination method of the present invention is as follows:
A, weighting raw materials;
B, Jia Shui decoct crude drug according to a conventional method, get decoction liquor, filter, and add acceptable accessories and make medicament;
Perhaps, pulverize crude drug, mix, add acceptable accessories and make powder, tablet, capsule, pill.
Cardiovascular and cerebrovascular vessel patient, how with the sclerosis of tremulous pulse medicated porridge shape sample, though its cause of disease is complicated, pathological research finds that the blood vessel lipidosis is one of important cause of disease.Therefore, blood fat reducing, vessel softening are one of prefered methods of treatment primary disease; Simultaneously,, increase the coronary flow of cerebrovascular, kidney blood vessel and heart, reduce too high blood pressure, just can reach the purpose of treatment must aim at the pathogenesis of disease again by blood vessel dilating.Theory of Chinese medical science thinks, pathogens such as the generation of cardiovascular and cerebrovascular disease and its void, wet, wind, expectorant, the stasis of blood are relevant, serve as obviously to show with syndrome of deficiency of QI, syndrome of blood stasis especially.The unable promotion nutrient blood of the deficiency of vital energy normally moves, and must cause blood-vessel obstructive obstructed, and QI and blood does not reach, and then gives birth to wind, expectorant, damp.By tonifying vital QI, spleen invigorating is washed turbid, and dredging the meridian reaches the purpose of " healthy energy deposit in, heresy can not be done ".The Radix Astragali in the pharmaceutical composition of the present invention, Radix Ginseng, Cortex Acanthopancis master replenishing QI to invigorate the spleen and set upright; Join Radix Bupleuri, Rhizoma Alismatis, Flos Lonicerae, Fructus Trichosanthis, Radix Et Rhizoma Rhei master dispelling wind evil, remove phlegm-damp; 5 Fructus Crataegis, Radix Notoginseng, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis master dredge the resistance of the heart feeling pulse stasis of blood, and Radix Puerariae, the logical brain feeling pulse of Rhizoma Chuanxiong master block,, bring into play the effect of Synergistic, reach the purpose for the treatment of both the principal and secondary aspects of a disease.Wherein Radix Et Rhizoma Rhei can adopt Radix Et Rhizoma Rhei, Radix et Rhizoma Rhei (stir-fried with wine), Radix Et Rhizoma Rhei, but according to the property of medicine, preferred Radix et Rhizoma Rhei (stir-fried with wine).
Further, pharmaceutical composition of the present invention has the following advantages:
L, reduce the absorption of intestinal, prevent and reduce hyperlipemia, reduce the tremulous pulse lipidosis, prevent sclerosis of blood vessels cholesterol.
2, blood vessel dilating reduces Peripheral resistance, brings high blood pressure down; Also has the effect of blood pressure lowering by suppressing epinephrine; The blocking-up sympathetic nerve is also arranged to vasoconstriction and the effect of blood pressure lowering.
3, have coronary blood flow increasing, reduce myocardial oxygen consumption and improve the unusual effect of hemorheology, help the control of cardiovascular disease.
4, have function by blood brain barrier, thus expansion of cerebral vascular, and the cerebral blood flow increasing amount is improved cerebral blood supply.
5, blood flow is carried out two-ways regulation, both can prevent out hyperhematosis, can make the blood stasis that has gone out again comparatively fast by metabolism, thus unexpected sick to treatment hemorrhagic and ischemic cerebral vascular, have unique curative effect.
6, excitor nerve maincenter, the phagocytic function of increase reticuloendothelial system improves body resistance against diseases.
Below beneficial effect by clinical statistics proof pharmaceutical composition of the present invention.
It is clinical that the inventor adopts pharmaceutical composition of the present invention to be applied to, and specifically is to be made into capsule to use, and capsule preparation method thereof is as follows:
1, with the weight ratio weighting raw materials of 12 parts of the Radixs Astragali, 3 parts of Cortex Acanthopanciss, 2 parts of Radix Et Rhizoma Rhei, 3 parts of Fructus Crataegis, 4 parts of Radix Notoginseng, 3 parts of Rhizoma Chuanxiongs, 3 parts of Radix Angelicae Sinensis, pulverize, mix, encapsulated, make capsules A (every capsules contains crude drug 3g).
2, with the weight ratio weighting raw materials of 12 parts of the Radixs Astragali, 5 parts of Radix Ginsengs, 3 parts of Cortex Acanthopanciss, 2 parts of Radix Bupleuri, 2 parts of Rhizoma Alismatis, 2 parts of Flos Loniceraes, 2 parts of Fructus Trichosanthis, 2 parts of Radix Et Rhizoma Rhei, 1 part of Radix Puerariae, 3 parts of Fructus Crataegis, 4 parts of Radix Notoginseng, 4 parts of Radix Salviae Miltiorrhizaes, 3 parts of Rhizoma Chuanxiongs, 3 parts of Radix Angelicae Sinensis, pulverize, mix, encapsulated, make capsule B (every capsules contains crude drug 3g).
Use capsules A and B and be used for the treatment of cerebral infarction, cerebral hemorrhage, coronary heart disease, statistical data sees Table 1-4:
Table 1 cerebral infarction clinical statistics
Group The example number Recovery from illness Produce effects Effectively Invalid Total effective rate
Test group (capsules A) 32 6 15 6 5 74.4%
Test group (capsule B) 50 9 24 15 2 96.0%
Matched group (big means of subsistence ball) 30 1 8 16 5 83.3%
There was a significant difference to treatment cerebral infarction curative effect for two groups of medicines, and test group is better than matched group (learn by statistics and handle P<0.05).
Table 2 cerebral hemorrhage (stable phase) clinical statistics
Group The example number Recovery from illness Produce effects Invalid Total effective rate
Test group (capsules A) 33 9 18 6 81.8%
Test group (capsule B) 30 8 20 2 93.3%
Matched group (ginseng restorative bolus) 26 3 16 7 73.1%
There was a significant difference to treatment cerebral hemorrhage (stable phase) curative effect for two groups of medicines, and test group obviously is better than matched group (learn by statistics and handle P<0.01).
Table 3 coronary heart disease (capsules A)
The example number The 24h produce effects The 48h produce effects Invalid Total effective rate
Myocardial infarction 34 ?18 ?10 6 82.4%
Angina pectoris 33 ?21 ?11 1 97.0%
Wherein, the coronary heart disease clinical observation is totally 67 examples, and 34 examples are suffered from myocardial infarction; 33 examples suffer from angina pectoris, and are obvious by taking medicine composite for curing coronary heart disease effect of the present invention.
Table 4 coronary heart disease clinical statistics (capsule B)
The example number The 24h produce effects The 48h produce effects Invalid Total effective rate
Myocardial infarction 45 ?20 ?20 5 88.9%
Angina pectoris 45 ?19 ?25 1 97.8%
Wherein, the coronary heart disease clinical observation is totally 90 examples, and 45 routine myocardial infarction and angina pectoriss are respectively arranged, and is obvious by taking medicine composite for curing coronary heart disease effect of the present invention.
The inventor in application process, when also finding to take capsules A and capsule B, for suffering from hypertension, hyperlipemia, the patient of fatty liver can improve symptoms such as its hypertension, blood fat height.Statistical data sees Table 5-6.
Table 5 hypertension clinical statistics
Group The example number The 12h produce effects The 24h produce effects Invalid Total effective rate
Test group (capsules A) 43 ?12 ?28 3 93.0%
Test group (capsule B) 42 ?20 ?21 1 97.6%
FUFANG LUOBUMA PIAN 40 ?30 ?8 2 95.0%
By above-mentioned statistical description, medicine composite for curing hypertension effect of the present invention is remarkable.
Table 6 high fat of blood clinical statistics
Group The example number Produce effects Effectively Invalid Total effective rate
Test group (capsules A) 46 30 8 8 82.6%
Test group (capsule B) 49 39 6 4 91.8%
Folium Ginkgo 43 22 10 11 74.4%
By above-mentioned statistical description, medicine composite for curing high fat of blood effect of the present invention is remarkable, and obviously is better than the existing product Folium Ginkgo.
Pharmaceutical composition of the present invention is year clinical observation surplus about ten, determine with the Radix Astragali, Radix Ginseng, Cortex Acanthopancis, Radix Bupleuri, Rhizoma Alismatis, Flos Lonicerae, Fructus Trichosanthis, Radix Et Rhizoma Rhei, Radix Puerariae, Fructus Crataegi, Radix Notoginseng, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong behind the screening prescription at last and work as to be classified as crude drug, therapeutic effect the best, and determine that its proportion relation is: 12 parts of the Radixs Astragali, 5 parts of Radix Ginsengs, 3 parts of Cortex Acanthopanciss, 2 parts of Radix Bupleuri, 2 parts of Rhizoma Alismatis, 2 parts of Flos Loniceraes, 2 parts of Fructus Trichosanthis, 2 parts of Radix Et Rhizoma Rhei, 1 part of Radix Puerariae, 3 parts of Fructus Crataegis, 4 parts of Radix Notoginseng, 4 parts of Radix Salviae Miltiorrhizaes, 3 parts of Rhizoma Chuanxiongs, 3 parts of therapeutic effect of Radix Angelicae Sinensis are clear and definite, stable curative effect.

Claims (10)

1. be used for the pharmaceutical composition of supplementing qi and invigorating vasculum, it is characterized in that: it is to be prepared from by following materials of weight proportions medicine:
Radix Astragali 9-16 part, Cortex Acanthopancis 2-5 part, Radix Et Rhizoma Rhei 1-5 part, Fructus Crataegi 2-5 part, Radix Notoginseng 3-6 part, Rhizoma Chuanxiong 2-5 part, Radix Angelicae Sinensis 2-9 part.
2. the pharmaceutical composition that is used for supplementing qi and invigorating vasculum according to claim 1 is characterized in that: it is to be prepared from by following materials of weight proportions medicine:
12 parts of the Radixs Astragali, 3 parts of Cortex Acanthopanciss, 2 parts of Radix Et Rhizoma Rhei, 3 parts of Fructus Crataegis, 4 parts of Radix Notoginseng, 3 parts of Rhizoma Chuanxiongs, 3 parts of Radix Angelicae Sinensis.
3. the pharmaceutical composition that is used for supplementing qi and invigorating vasculum according to claim 1 is characterized in that: it is with the Radix Astragali, Cortex Acanthopancis, Radix Et Rhizoma Rhei, Fructus Crataegi, Radix Notoginseng, Rhizoma Chuanxiong and ought be classified as crude drug, adds the medicament that acceptable accessories is prepared from.
4. be used for the pharmaceutical composition of supplementing qi and invigorating vasculum, it is characterized in that: it is to be prepared from by following materials of weight proportions medicine:
Radix Astragali 9-16 part, Radix Ginseng 3-5 part, Cortex Acanthopancis 2-5 part, Radix Bupleuri 1-5 part, Rhizoma Alismatis 1-5 part, Flos Lonicerae 1-3 part, Fructus Trichosanthis 1-3 part, Radix Et Rhizoma Rhei 1-5 part, Radix Puerariae 1-3 part, Fructus Crataegi 2-5 part, Radix Notoginseng 3-6 part, Radix Salviae Miltiorrhizae 3-9 part, Rhizoma Chuanxiong 2-5 part, Radix Angelicae Sinensis 2-9 part.
5. the pharmaceutical composition that is used for supplementing qi and invigorating vasculum according to claim 4 is characterized in that: it is to be prepared from by following materials of weight proportions medicine:
12 parts of the Radixs Astragali, 5 parts of Radix Ginsengs, 3 parts of Cortex Acanthopanciss, 2 parts of Radix Bupleuri, 2 parts of Rhizoma Alismatis, 2 parts of Flos Loniceraes, 2 parts of Fructus Trichosanthis, 2 parts of Radix Et Rhizoma Rhei, 1 part of Radix Puerariae, 3 parts of Fructus Crataegis, 4 parts of Radix Notoginseng, 4 parts of Radix Salviae Miltiorrhizaes, 3 parts of Rhizoma Chuanxiongs, 3 parts of Radix Angelicae Sinensis.
6. the pharmaceutical composition that is used for supplementing qi and invigorating vasculum according to claim 4, it is characterized in that: it is with the Radix Astragali, Radix Ginseng, Cortex Acanthopancis, Radix Bupleuri, Rhizoma Alismatis, Flos Lonicerae, Fructus Trichosanthis, Radix Et Rhizoma Rhei, Radix Puerariae, Fructus Crataegi, Radix Notoginseng, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong and ought be classified as crude drug, adds the medicament that acceptable accessories is prepared from.
7. according to claim 3 or the 6 described pharmaceutical compositions that are used for supplementing qi and invigorating vasculum, it is characterized in that: described medicament is powder, granule, tablet, capsule, pill or oral liquid.
8. preparation of drug combination method that is used for supplementing qi and invigorating vasculum is characterized in that its step is as follows:
A gets crude drug: Radix Astragali 9-16 part, Cortex Acanthopancis 2-5 part, Radix Et Rhizoma Rhei 1-5 part, Fructus Crataegi 2-5 part, Radix Notoginseng 3-6 part, Rhizoma Chuanxiong 2-5 part, Radix Angelicae Sinensis 2-9 part;
B, Jia Shui decoct crude drug according to a conventional method, get decoction liquor, filter, and add acceptable accessories and make medicament; Or
Pulverize crude drug, mix, add acceptable accessories and make powder, tablet, capsule, pill.
9. preparation of drug combination method that is used for supplementing qi and invigorating vasculum is characterized in that its step is as follows:
A gets crude drug: Radix Astragali 9-16 part, Radix Ginseng 3-5 part, Cortex Acanthopancis 2-5 part, Radix Bupleuri 1-5 part, Rhizoma Alismatis 1-5 part, Flos Lonicerae 1-3 part, Fructus Trichosanthis 1-3 part, Radix Et Rhizoma Rhei 1-5 part, Radix Puerariae 1-3 part, Fructus Crataegi 2-5 part, Radix Notoginseng 3-6 part, Radix Salviae Miltiorrhizae 3-9 part, Rhizoma Chuanxiong 2-5 part, Radix Angelicae Sinensis 2-9 part;
B, Jia Shui decoct crude drug according to a conventional method, get decoction liquor, filter, and add acceptable accessories and make medicament;
Or the pulverizing crude drug, mix, add acceptable accessories and make powder, tablet, capsule, pill.
10. the purposes of each described pharmaceutical composition of claim 1-7 in the medicine of preparation treatment cerebral infarction, cerebral hemorrhage, coronary heart disease, hypertension, hyperlipemia, fatty liver.
CN2009103123939A 2009-12-28 2009-12-28 Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof Expired - Fee Related CN101708237B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009103123939A CN101708237B (en) 2009-12-28 2009-12-28 Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009103123939A CN101708237B (en) 2009-12-28 2009-12-28 Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof

Publications (2)

Publication Number Publication Date
CN101708237A CN101708237A (en) 2010-05-19
CN101708237B true CN101708237B (en) 2011-06-29

Family

ID=42401058

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009103123939A Expired - Fee Related CN101708237B (en) 2009-12-28 2009-12-28 Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof

Country Status (1)

Country Link
CN (1) CN101708237B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103212044B (en) * 2013-04-08 2015-04-01 周丽英 Traditional Chinese medicine composition for treating cardiovascular diseases
CN104107424B (en) * 2014-07-31 2015-07-15 杜志政 Qi cultivating thrombolytic medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof
CN105770134A (en) * 2016-01-13 2016-07-20 青岛市市立医院 Traditional Chinese medicine for treating hyperlipemia
CN105853626A (en) * 2016-05-24 2016-08-17 内蒙古中安类风湿骨关节病专科医院有限责任公司 Traditional Chinese medicine composition for treating fatty liver and hyperlipidemia
CN108853202A (en) * 2018-08-10 2018-11-23 因之彩生物科技(武汉)有限公司 A kind of pharmaceutical preparation that treating fatty liver and its application
CN114949086B (en) * 2022-04-25 2023-08-22 西南医科大学附属中医医院 Composition for treating cerebral hemorrhage
CN116870093A (en) * 2023-02-23 2023-10-13 魏峰松 Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1092286A (en) * 1993-12-04 1994-09-21 温长路 Chinese traditional medicine stop pain health care hath liquid
CN1113778A (en) * 1994-06-17 1995-12-27 殷广全 Preparation for treating senile diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1092286A (en) * 1993-12-04 1994-09-21 温长路 Chinese traditional medicine stop pain health care hath liquid
CN1113778A (en) * 1994-06-17 1995-12-27 殷广全 Preparation for treating senile diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
赵新峰.活血化瘀法治疗心病用药探析.《中华中医药学刊》.2007,第25卷(第5期), *
齐君.中药降血脂作用的研究进展.《内蒙古中医药》.2007,(第1期), *

Also Published As

Publication number Publication date
CN101708237A (en) 2010-05-19

Similar Documents

Publication Publication Date Title
CN100457176C (en) Chinese medicinal preparation for curriculum of physical and fatigue reducing
CN101708237B (en) Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof
CN103083582B (en) Medicine for treating hyperlipidemia
CN104027500A (en) Traditional Chinese medicinal formula for treating high blood fat, hypercholesterolemia and high blood viscosity
CN101711847B (en) Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis
CN101780223B (en) Traditional Chinese medicine with integral coordination function for treating ischemic cerebrovascular disease
CN101642542B (en) Capsule for nourishing liver and kidney and reducing blood pressure
CN101366903B (en) Traditional Chinese medicine composition for treating climacteric syndrome
CN102198228A (en) Chinese medicinal preparation for treating hypertension
CN104043045A (en) Pharmaceutical composition for treating optic atrophy
CN102100873B (en) Chinese patent medicine for treating heart cerebrovascular diseases and preparation method thereof
CN101496892B (en) Oral Chinese patent medicine for treating cardiovascular disease
CN101428131B (en) Medicament for treating tympany
CN105250427A (en) Pharmaceutical composition for treating heart diseases
CN101564484A (en) Chinese traditional medicine combination for treating mastosis and preparing method
CN101658636B (en) Chinese medical composition for treating coronary heart disease
CN103169855A (en) Drug composition for treating chronic heart failure
CN101549057A (en) Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same
CN102631607B (en) Medicament for treating cardiovascular diseases and preparation method thereof
CN101278982A (en) Chinese medicine compound preparation for curing acute or chronic hepatitis B and method of preparing the same
CN104001026A (en) Medicine for treating myocardial ischemia
CN102302708A (en) Medicament for chronic kidney disease (kidney deficiency and blood stasis)
CN101612233B (en) Chinese medicine preparation for detumescence and analgesia
CN102225132A (en) Traditional Chinese medicine compound for treating hyperlipidaemia, cerebral arteriosclerosis and ischemic stroke and preparation method thereof
CN102805795B (en) Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110629

Termination date: 20131228